US Stock MarketDetailed Quotes

Eton Pharmaceutical (ETON)

Watchlist
  • 25.040
  • +0.610+2.50%
Close Apr 17 16:00 ET
  • 25.000
  • -0.040-0.16%
Post 20:01 ET
683.20MMarket Cap-147.29P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Eton Pharmaceutical (ETON) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
104.94%79.95M
82.72%21.28M
117.54%22.46M
108.60%18.93M
116.95%17.28M
23.29%39.01M
59.26%11.65M
46.90%10.32M
-24.36%9.07M
50.19%7.97M
Operating revenue
104.94%79.95M
82.72%21.28M
117.54%22.46M
108.60%18.93M
116.95%17.28M
23.29%39.01M
59.26%11.65M
46.90%10.32M
-24.36%9.07M
50.19%7.97M
Cost of revenue
138.53%37.21M
58.21%8.18M
263.10%14.6M
103.13%7M
150.79%7.42M
47.43%15.6M
40.40%5.17M
53.22%4.02M
48.94%3.45M
51.12%2.96M
Gross profit
82.56%42.74M
102.29%13.1M
24.64%7.86M
111.94%11.92M
96.94%9.86M
11.16%23.41M
78.40%6.48M
43.13%6.3M
-41.89%5.63M
49.64%5.01M
Operating expense
67.58%43.58M
81.91%10.64M
59.12%9.22M
56.51%13.4M
77.91%10.33M
16.87%26.01M
3.98%5.85M
17.01%5.79M
47.63%8.56M
-1.24%5.81M
Selling and administrative expenses
57.43%35.82M
31.82%8.86M
53.29%8.11M
73.26%9.69M
77.85%9.17M
20.19%22.75M
46.81%6.72M
21.96%5.29M
19.62%5.59M
-3.54%5.16M
-General and administrative expense
57.43%35.82M
31.82%8.86M
53.29%8.11M
73.26%9.69M
77.85%9.17M
20.19%22.75M
46.81%6.72M
21.96%5.29M
19.62%5.59M
-3.54%5.16M
Research and development costs
138.56%7.77M
304.36%1.78M
120.20%1.11M
24.98%3.71M
78.34%1.16M
-2.02%3.26M
-183.19%-871K
-17.89%505K
164.00%2.97M
21.68%651K
Operating profit
67.50%-844K
291.73%2.46M
-367.78%-1.36M
49.74%-1.48M
41.25%-470K
-117.87%-2.6M
131.56%629K
192.88%509K
-175.59%-2.94M
68.43%-800K
Net non-operating interest income expense
-206.69%-3.71M
7.89%-1.05M
-7,300.00%-592K
-1,907.69%-1.04M
-9,245.45%-1.03M
-340.76%-1.21M
-245.41%-1.14M
74.19%-8K
58.06%-52K
91.27%-11K
Non-operating interest expense
----
----
7,300.00%592K
1,907.69%1.04M
9,245.45%1.03M
----
----
-74.19%8K
-58.06%52K
-91.27%11K
Total other finance cost
206.69%3.71M
----
----
----
----
340.76%1.21M
----
----
----
----
Other net income (expense)
Income before tax
-19.70%-4.56M
376.71%1.41M
-490.22%-1.96M
15.67%-2.52M
-84.71%-1.5M
-452.69%-3.81M
74.56%-511K
186.53%501K
-165.52%-2.99M
69.51%-811K
Income tax
186.67%43K
-179.31%-69K
77.78%-28K
22.22%66K
74K
-93.93%15K
-64.78%87K
-126K
54K
0
Net income
-20.35%-4.6M
347.99%1.48M
-407.34%-1.93M
15.00%-2.59M
-93.83%-1.57M
-308.44%-3.82M
73.49%-598K
208.29%627K
-166.70%-3.04M
69.51%-811K
Net income continuous Operations
-20.35%-4.6M
347.99%1.48M
-407.34%-1.93M
15.00%-2.59M
-93.83%-1.57M
-308.44%-3.82M
73.49%-598K
208.29%627K
-166.70%-3.04M
69.51%-811K
Minority interest income
Net income attributable to the parent company
-20.35%-4.6M
347.99%1.48M
-407.34%-1.93M
15.00%-2.59M
-93.83%-1.57M
-308.44%-3.82M
73.49%-598K
208.29%627K
-166.70%-3.04M
69.51%-811K
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-20.35%-4.6M
347.99%1.48M
-407.34%-1.93M
15.00%-2.59M
-93.83%-1.57M
-308.44%-3.82M
73.49%-598K
208.29%627K
-166.70%-3.04M
69.51%-811K
Basic earnings per share
-13.33%-0.17
400.00%0.06
-450.00%-0.07
16.67%-0.1
-100.00%-0.06
-275.00%-0.15
77.78%-0.02
200.00%0.02
-166.67%-0.12
70.00%-0.03
Diluted earnings per share
-13.33%-0.17
350.00%0.05
-450.00%-0.07
16.67%-0.1
-100.00%-0.06
-275.00%-0.15
77.78%-0.02
200.00%0.02
-166.67%-0.12
70.00%-0.03
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 104.94%79.95M82.72%21.28M117.54%22.46M108.60%18.93M116.95%17.28M23.29%39.01M59.26%11.65M46.90%10.32M-24.36%9.07M50.19%7.97M
Operating revenue 104.94%79.95M82.72%21.28M117.54%22.46M108.60%18.93M116.95%17.28M23.29%39.01M59.26%11.65M46.90%10.32M-24.36%9.07M50.19%7.97M
Cost of revenue 138.53%37.21M58.21%8.18M263.10%14.6M103.13%7M150.79%7.42M47.43%15.6M40.40%5.17M53.22%4.02M48.94%3.45M51.12%2.96M
Gross profit 82.56%42.74M102.29%13.1M24.64%7.86M111.94%11.92M96.94%9.86M11.16%23.41M78.40%6.48M43.13%6.3M-41.89%5.63M49.64%5.01M
Operating expense 67.58%43.58M81.91%10.64M59.12%9.22M56.51%13.4M77.91%10.33M16.87%26.01M3.98%5.85M17.01%5.79M47.63%8.56M-1.24%5.81M
Selling and administrative expenses 57.43%35.82M31.82%8.86M53.29%8.11M73.26%9.69M77.85%9.17M20.19%22.75M46.81%6.72M21.96%5.29M19.62%5.59M-3.54%5.16M
-General and administrative expense 57.43%35.82M31.82%8.86M53.29%8.11M73.26%9.69M77.85%9.17M20.19%22.75M46.81%6.72M21.96%5.29M19.62%5.59M-3.54%5.16M
Research and development costs 138.56%7.77M304.36%1.78M120.20%1.11M24.98%3.71M78.34%1.16M-2.02%3.26M-183.19%-871K-17.89%505K164.00%2.97M21.68%651K
Operating profit 67.50%-844K291.73%2.46M-367.78%-1.36M49.74%-1.48M41.25%-470K-117.87%-2.6M131.56%629K192.88%509K-175.59%-2.94M68.43%-800K
Net non-operating interest income expense -206.69%-3.71M7.89%-1.05M-7,300.00%-592K-1,907.69%-1.04M-9,245.45%-1.03M-340.76%-1.21M-245.41%-1.14M74.19%-8K58.06%-52K91.27%-11K
Non-operating interest expense --------7,300.00%592K1,907.69%1.04M9,245.45%1.03M---------74.19%8K-58.06%52K-91.27%11K
Total other finance cost 206.69%3.71M----------------340.76%1.21M----------------
Other net income (expense)
Income before tax -19.70%-4.56M376.71%1.41M-490.22%-1.96M15.67%-2.52M-84.71%-1.5M-452.69%-3.81M74.56%-511K186.53%501K-165.52%-2.99M69.51%-811K
Income tax 186.67%43K-179.31%-69K77.78%-28K22.22%66K74K-93.93%15K-64.78%87K-126K54K0
Net income -20.35%-4.6M347.99%1.48M-407.34%-1.93M15.00%-2.59M-93.83%-1.57M-308.44%-3.82M73.49%-598K208.29%627K-166.70%-3.04M69.51%-811K
Net income continuous Operations -20.35%-4.6M347.99%1.48M-407.34%-1.93M15.00%-2.59M-93.83%-1.57M-308.44%-3.82M73.49%-598K208.29%627K-166.70%-3.04M69.51%-811K
Minority interest income
Net income attributable to the parent company -20.35%-4.6M347.99%1.48M-407.34%-1.93M15.00%-2.59M-93.83%-1.57M-308.44%-3.82M73.49%-598K208.29%627K-166.70%-3.04M69.51%-811K
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -20.35%-4.6M347.99%1.48M-407.34%-1.93M15.00%-2.59M-93.83%-1.57M-308.44%-3.82M73.49%-598K208.29%627K-166.70%-3.04M69.51%-811K
Basic earnings per share -13.33%-0.17400.00%0.06-450.00%-0.0716.67%-0.1-100.00%-0.06-275.00%-0.1577.78%-0.02200.00%0.02-166.67%-0.1270.00%-0.03
Diluted earnings per share -13.33%-0.17350.00%0.05-450.00%-0.0716.67%-0.1-100.00%-0.06-275.00%-0.1577.78%-0.02200.00%0.02-166.67%-0.1270.00%-0.03
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 17, the Iranian foreign minister announced the opening of the Strait of Hormuz to merchant ships, and Trump immediately posted a me Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -